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Background and objective: Among substances that have a signiﬁcant eﬀect on sleep are stimulants, including
amphetamines. As there are few studies assessing sleep quality in methamphetamine withdrawal this study
aims to evaluate changes in sleep quality of methamphetamine dependent patients during early remission
period by controlling depression and anxiety as confounding variables.
Methods: This study was conducted in Mashhad, Iran. Ninety amphetamine dependent patients, who were
admitted in residential centers during 2012–2014 and met our inclusion criteria, were chosen by purposive
nonprobability sampling method. Sleep quality was assessed by Pittsburg sleep questionnaire, in the ﬁrst,
second, and after the fourth week of abstinence. Additionally all participants were assessed by Beck Depression
Inventory-2 and Beck Anxiety Inventory for controlling depressive and anxiety symptoms.
Results: The prevalence of improper quality of sleep was very high (97.8%) within the ﬁrst week of withdrawal,
but it reduced considerably four weeks after abstinence (52.2%), which was statistically signiﬁcant (P=0.00).
The variations of depression and anxiety levels within four weeks after quitting methamphetamine, have low
impact on variation of patients' sleep quality (adjusted R2 < 0.5). Furthermore, the eﬀectiveness of these two
intervening variables on patients' quality of sleep was dwindled over time after abstinence.
Conclusions: This study showed that the patients' quality of sleep improved signiﬁcantly four weeks after
abstinence and its variation was independent from variations in anxiety and depressive symptoms.
1. Introduction
Sleep disorders have a signiﬁcant role in the general and clinical
health of the society [1]. They could be an independent clinical disorder
or a symptom of a clinical syndrome. They usually have direct and
indirect eﬀects on the daily functioning and quality of life of suﬀerer
and could lead to signiﬁcant healthcare costs for the society [2–5].
Each year they aﬀect many individuals and cause intrapersonal and
interpersonal impairments [6]. To date, many studies have focused to
ﬁnd out probable etiologies of sleep disturbances and they have shown
us the signiﬁcant correlation between sleep disorders and substance
use [7–9]. Among the substances which have a signiﬁcant eﬀect on the
sleep condition are stimulants, including amphetamines [10].
Amphetamines are used for curbing the appetite, increasing attention
and concentration, increasing energy and also as an illicit recreational
substance [11,12].
It seems that the eﬀect of stimulants on the sleep-wake cycle is fully
discussed in the literature. However, our knowledge has mainly derived
from the studies performed on the stimulant medications (e.g. methyl-
phenidate) or cocaine; and what is said about the eﬀects of ampheta-
mines on sleep-wake cycleis basically generalization of the results of
studies which have been done on the other drugs [13]. Nevertheless
there are several reasons that amphetamine and amphetamine-like
drugs, especially methamphetamine, have diﬀerently inﬂuenced the
consumers. Amphetamines are known to have longer half-life (9–15 h)
in comparison to other stimulants [14]. They have proven neurotoxic
eﬀects through reactive oxygen species and hyperthermia, causing
axonal injury, especially in synaptic terminals [15,16]. They also lead to
signiﬁcant changes in neurotransmission of glutamate, dopamine,
serotonin and norepinephrine causing major behavioral changes
[17−20]. Therefore, independent assessment of neurological and
psychological alteration of brain activity in methamphetamine abusers
is warranted.
According to few researches to reveal the eﬀects of amphetamines
on sleep-wake cycle, it has been suggested that consuming ampheta-
mines usually leads to insomnia immediately after usage [10]. It can
also lead to hypersomnia in the early withdrawal states [21]. In 1960s
Rechtschaﬀenet al. showed that a small amount of amphetamine can
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increase sleep latency and decrease REM sleep [22]. Withdrawal from
amphetamine, on the other hand, can lead to increased REM sleep,
lasting for several days [23]. Later in 1990s, Mitler et al. reported same
results and showed that methamphetamine can decrease sleep eﬃ-
ciency in low doses (10 mg) [24], although sleep increases for 3–5 days
after withdrawal [23]. But other studies brought us more confusing
ﬁndings. There are also reports of delayed insomnia in users attempt-
ing to quit long-term amphetamine use after the 3–5 initial days [23].
Furthermore, the impact of anxiety and depression on sleep quality is
not negligible. Stimulants often accompany with anxiety states short
after consuming and depressive states in long term use, while patients
usually develop depressive symptoms short after quitting them [25].
According to frequent reports, depression and anxiety could have
deteriorating eﬀects on sleep quality [26,27]. Therefore, sleep quality
of patients who stop using methamphetamines, simply could inﬂuence
by changes in perceived anxiety or depression. Unfortunately there
have not been adequate studies on sleep disorders in amphetamine
users.
Considering the importance of sleep health, many studies have
examined sleep quality as a marker of general health [28]. Sleep
quality, which is a self evaluation of sleep, is considered more
important than sleep quantity in the assessment of general health
[29,30]. Poor sleep quality is associated with fatigue and impaired
mental and occupational functions [31]. This index is aﬀected by many
sleep-wake cycle disorders and studies have shown that stimulants
aﬀect sleep quality as well [32]. As there are not enough studies
assessing sleep quality in methamphetamine dependent patients dur-
ing prolonged abstinence, especially after prolonged use [33]; the
present study aims to evaluate subjective changes in sleep quality of
methamphetamine dependent patients during early remission period.
2. Methods
2.1. Subjects
The present study was designed in cross-sectional fashion and was
performed in Mashhad City during 2012–2014. Mashhad is the second
largest city in Iran, with a population of more than three million
people. According to national strategies for treatment of substance use
disorder in Iran, there are some residential centers for the treatment of
substance use disorders which admit volunteers for almost 3 months.
Although individual or group supportive psychotherapies and over-the-
counter (OTC) medications are oﬀered in these residential centers,
patients have no access to any kind of substances and relapse is
prevented in the initial phases of withdrawal, when craving is at its
highest. Therefore, patients experience abstinence in these controlled
environments during institutionalization. Since there is no psychiatric
medication in these residential programs, patients with signiﬁcant
mood and anxiety symptoms, ideas of harm to self or others, intoxica-
tion, and psychotic disorders are not allowed to be admitted and are
referred to other type of outpatient or inpatient treatment centers. As
there is no need for speciﬁc pharmacotherapy in the treatment of
amphetamine dependence disorder [14], these centers present an
opportunity for researchers to evaluate patients, who do not require
any kind of pharmacotherapy, for long periods after reaching absti-
nence. This study was performed in collaboration of participants of
these residential centers in Mashhad.
2.2. Procedure
After explaining the project to patients at the beginning of admis-
sion to the residential centers, every patient who consented to
participate in the study, went through a psychiatric interview tobe
assessed for the inclusion criteria. Then sleep quality was assessed by
Pittsburg Sleep Quality Index (PSQI). According to McGregor et al. the
methamphetamine withdrawal time-coursecould be divided into acute
(ﬁrst 7–10 days) and sub-acute (11th −21st days) phases [34]; so, the
initial assessment of sleep quality was done in the ﬁrst week of
initiation of withdrawal (before day 3) to rate sleep quality in the acute
phase, the second assessment was done in the second week (days 11–
14) to rate sleep quality in the sub-acute phase, and the last assessment
was done after the 4th week (days 28–35) of abstinence, to rate sleep
quality in the primary remission period(according to DSM-IV-TR
criteria).
Participants of the study were screened by two trained interviewers
(a psychiatrist and a psychologist) by means of structural interviewing.
The inclusion criteria was age between 18 and 60 years-old, normal IQ
(over 100), methamphetamine dependence disorder according to
DSM-IV-TR criteria, no comorbid dependence on other substances
except nicotine (occasional abuse of alcohol, opioids, benzodiazepines,
cannabis to the extent not warranting a diagnosis of dependency
according to DSM-IV-TR was acceptable), not taking medications
aﬀecting sleep-wake cycle (in this study, antihistamines among
OTCs), no methamphetamine induced disorder other than sleep
disorder, no comorbid axis I psychiatric disorder (unrelated to
methamphetamine use), and no medical condition aﬀecting sleep.
Every patient who fulﬁlled the inclusion criteria and accepted the
written informed consent could participate in the study, so the
sampling method was purposive nonprobability sampling.
Participants opting to quit the study or the ones discharged before
the third assessment were excluded from the study. Sampling was
started form March 2012 to August 2014. During this period of time,
ninety patients completed the study. Considering the high comorbidity
of depressive and anxiety symptoms with sleep disorders [35,36],
probable high rates of depressive and anxiety symptoms in the ﬁrst
days of joining to any residential program and also the high frequency
of these symptoms in the initial phase of withdrawal from stimulants
[34], all participants were given Beck Depression Inventory II (BDI-II)
and Beck Anxiety Inventory (BAI) in addition to PSQI for controlling
the anxiety and depressive symptoms as confounding variables. All
questionnaires were anonymous to prevent any disclosure of personal
information and participants were identiﬁed with an anonymous
number assigned to their proﬁle.
2.3. Instruments
The questionnaires used in this study were:
2.3.1. Pittsburgh Sleep Quality Index (PSQI)
Sleep quality is aﬀected by several factors, and these factors
signiﬁcantly diﬀer in diﬀerent individuals. Therefore, it seems that a
self-report questionnaire is best ﬁtted to assess sleep disorders [3,37].
The PSQI has 7 components and the sum of their scores make the
global PSQI score. The participant score the questionnaire on a likert
scale from 0 (best condition) to 3 (worst condition), so the minimum
score is 0 and the maximum is 21. A global PSQI score over 5 is
associated with poor sleep quality. This questionnaire has been studied
in various populations and its score is moderately to highly correlate
with the sleep quality reported by the patients [38−41].
2.3.2. Beck Depression Inventory-II (BDI-II)
This is a self-report 21-item questionnaire which assesses depres-
sive symptoms. The total score range is from 0 to 63, the higher scores
representing a more severe depression. This questionnaire has a high
validity in all populations and in depressed and non-depressed
individuals which has been reported 0.70–0.90 in diﬀerent studies
[42,43].
2.3.3. Beck Anxiety Inventory (BAI)
Beck Anxiety Inventory is a 21-item questionnaire, assessing the
anxiety state of individuals. The total scores range from 0 to 63, higher
scores indicating a more severe anxiety. The validity of this scale has
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been veriﬁed in several studies [44,45].
2.4. Statistical analysis
After data collection, it was analyzed with SPSS software version
11.5. First the distribution of results was assessed by Kolmogorov–
Smirnov test. As none of sleep quality, anxiety and depression of
participants had normal distribution, we used Wilcoxon signed-rank
test to compare the distributions of variables through consecutive
assessments. Also we need to estimate the predictive value of variations
in anxiety and depression as independent variables on the variation in
sleep quality of participants as dependent variable; so, we used general
linear regression model and entered variation in both depression and
anxiety of participants in a single step analysis to predict the variation
in the sleep quality (enter method).
3. Results
In this study, a total of 90 patients with methamphetamine
dependence disorder were examined in terms of quality of sleep and
symptoms of depression and anxiety through three consecutive mea-
surements. Table 1 summarizes the patients' demographic variables. As
shown in Table 1 most of the participants were males, who were
married and employed. Preferred route of using was smoking metham-
phetamine with pipe in all participants. The improper quality of sleep,
which is shown with PSQI > 5, was very common within the ﬁrst days
of withdrawal from methamphetamine (97.8% of participants in the
ﬁrst assessment), while its frequency was reduced considerably four
weeks after being abstinent (52.2% of participants in the third
assessment) (Table 1).
Figs. 1–3 are the scatter diagrams that show the sleep quality
results obtained through three assessments in the participants.
According to the diagrams, distribution pattern of sleep quality index
of the participants shows minimal changes between the ﬁrst and
second evaluations (Figs. 1 and 2), but it appears that the last
assessment which was done one month after quitting the substance
has diﬀerent pattern of distribution (Fig. 3). Given the results of the
Table 2, mean sleep quality scores of the participants has reduced
signiﬁcantly in the third assessment in comparison to the previous
assessments (P=0).
Table 3 shows the mean changes of the sleep quality, depression
and anxiety of the participants through the three consecutive measure-
ments. The data indicates that the index of sleep quality of participants
has considerable reduction four weeks after the complete abstinence
from methamphetamine, yet the scores of BDI-II and BAI decreased in
repeated assessments too. Considering the fact that the alteration in
depression and anxiety symptoms can inﬂuence the patients' quality of
sleep, the multivariate regression model was used to measure the
impact of the decreased scores of patients' depression and anxiety on
the decreased index of sleep quality. Table 3 shows the respective
results. Although the variations of depression and anxiety levels within
four weeks after stopping amphetamine use was signiﬁcantly eﬀective
in prediction of patients' variation of sleep quality, the measured
impact was low (adjusted R2 < 0.5). Furthermore, the impact of these
two intervening variables on patients' quality of sleep was dwindled
over time after quitting amphetamine use (Table 4).
Table 1
Demographic variables and PSQI scores of the participants of the study.
Variable Frequency
Age (years) 32.1 ± 6.9
Gender (individuals) Male 74
Female 16
Marital status (individuals) Single 29
Married 43
Divorced 18
Occupation (individuals) Unemployed 28
Employed 62
Quality of sleep in the beginning of study
(individuals)
PSQI > 5 88
PSQI≤5 2
Quality of sleep at the end of study (individuals) PSQI > 5 47
PSQI≤5 43
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Fig. 1. Pattern of frequency distribution for the sleep quality of participants at days 1–3
of the study (ﬁrst assessment).
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Fig. 2. Pattern of frequency distribution for the sleep quality of participants at days 11–
14 of the study (second assessment).
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Fig. 3. Pattern of frequency distribution for the sleep quality of participants at days 28–
35 of the study (third assessment).
Table 2
Comparison of the quality of sleep of participants between three stages of the study.
Variable Z P
Quality of sleep Comparison between the first and second
measurement
0.48 0.63
Comparison between the ﬁrst and third
measurement
8.25 0.00
Comparison between the second and third
measurement
8.20 0.00
*using Wilcoxon signed-rank test
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4. Discussion
In this study the prevalence of improper sleep quality was reported
97.8% and 52.2% within days 1–5 and by the end of fourth week (days
28–35) of abstinence from methamphetamine, respectively. Repeated
measurements of patients' depression and anxiety levels indicated that
the improved depression and anxiety levels in patients, within four
weeks after quitting methamphetamine use, can totally predict 15% of
the improved sleep quality in patients. In other words, 85% of the
reported improvement which happened within four weeks after total
abstinence can be attributed to stopping use of methamphetamine,
itself.
Results showed that the improper quality of sleep during the early
days of treatment was reported very high (97.8%). Since the quality of
sleep, which is measured by PSQI, is the outcome of several parameters
including the general description of the subject on his/her own
sleeping, the sleep latency, sleep duration, sleep suﬃciency, sleep
maintenance and morning performance, any change in the mentioned
factors may decrease sleep quality [41]. There are reports about the
reduced sleep duration, the prolonged delay in falling sleep, decreased
sleep duration and more frequent spontaneous awakenings from sleep
within 3–5 days after using amphetamines [13]. On the other hand, it
has been suggested that quitting methamphetamine use may increase
the daytime drowsiness [28]. Therefore, the low quality of sleep due to
using methamphetamines is expected. However, the high prevalence of
disturbed sleep inthe early days of study demonstrates that metham-
phetamines broadly aﬀect the brain centers which are tasked with
regulating the sleep-wake cycle. In fact, 88 out of 90 participants
reported the low-quality sleep at the beginning of the study; while
analysis of low-quality sleep prevalence in other chronic diseases using
similar tool (PSQI) showed lower values. For instance, studies have
shown that sleep quality is usually low in 75% of patients with end-
stage renal disease who are being treated with dialysis [46], 56% of
patients suﬀering systemic lupus erythematosus [47], 47% of patients
with Parkinson disease [48] and 71% of patients with type 2 diabetes
mellitus [49]. Thus, the very high prevalence of low-quality sleep in
methamphetamines users emphasizes the importance of sleep pro-
blems issues in treatment protocols. On the other hand, although the
drug tolerance is common after long-term use of most stimulants, the
high rate of sleep disturbance at the beginning of this study indicated
that tolerance to the disturbing eﬀects of methamphetamine on sleep-
wake cycle is not observed in methamphetamines abusers, even in
severe cases such as methamphetamine dependence disorder patients.
Given the Figs. 1–3 and Table 2, it was found that the quality of
sleep did not change considerably within the subacute phase of
amphetamine withdrawal syndrome rather the early days of the
treatment. McGregor et al. pointed that the subacute phase of
methamphetamine withdrawal syndrome is characterized by the sligh-
ter symptoms of the acute phase syndrome [34]. But in the present
study, sleep disturbances remained in subacute phase and no improve-
ment was observed between the ﬁrst and second evaluation of sleep
quality (P=0.63). Even it seems that some patients have experienced
worse sleep quality in subacute phase of withdrawal that the acute
phase, therefore in patients with methamphetamine dependence dis-
order, even fourteen-day duration after the last use of the drug is not
suﬃcient for restoring the neurobiological damages in brain centers
regulating the sleep-wake cycle and the patients could not clinically feel
any improvement in their quality of sleep. Thus, it can be concluded
that the neuronal damage is intensive and the recovery phase is slow
for those who suﬀer from methamphetamine-induced sleep disorders.
It is noteworthy that due to polysomnography protocols it is recom-
mended that the patients with the background of stimulant use should
stop using the drug at least for one week before polysomnography.
Based on the given results, it seems that polysomnographic evaluation
for the methamphetamine users should not be conducted even in the
second week of abstinence. Also, the positive correlation between sleep
disorders and craving in patients with methamphetamine dependency
demonstrates the importance of managing patients' sleep problems
during either acute or subacute phases of the treatment.
Results showed that more than half of the participants still suﬀered
from the severe disturbances in their sleep even in the ﬁfth week after
reaching abstinence from amphetamines and amphetamine-like deri-
vates. This ﬁnding does not support the results observed after
prescribing amphetamines for the rhesus macaque. In a study con-
ducted on methamphetamine self-administration in the rhesus maca-
que, Anderson et al. showed that the quality of sleep will be normal
again immediately after stopping methamphetamine prescription [7].
A disturbed sleeping condition lingering for more than a month after
quitting methamphetamine showed that in methamphetamine depen-
dents, behavioral symptoms attributed to withdrawal from metham-
phetamine are not simply an opposite form of behavioral symptoms
which are present in the course of using these drugs. This can support
the hypothesis that the neurobiological pathways aﬀecting by using
drugs, which are in charge of the behavioral phenomena of substance
use disorders, are separated from those aﬀecting during withdrawal
syndromes. It seems that a kind of adaptation is developed in sleep-
wake cycle-related systems in brain during abusing amphetamine and
amphetamine-like substances, so withdrawal from methamphetamine
is not simply an opposite form of using it. According to some studies,
this adaptation is caused by the formation of a secondary pacemaker as
an opponent process to regulate sleep-wake cycle out of the suprachias-
matic nucleus. As a result, quitting amphetamines, while activation of
the opponent processes remained in this system, results in some more
durable symptoms in patients' sleep-wake cycle [13].
Present study showed that the patients' quality of sleep variation
was independent from the patients' aﬀective symptoms. These aﬀective
symptoms could be generated in the patients of residential centers,
Table 3
Quality of sleep, depression and anxiety of the participants at three stages of the study.
Variable Timing of Evaluation
First Assessment
(days 1–5)
Second Assessment
(days 11–14)
Third Assessment
(days 28–35)
Quality of sleep 13.6 ± 3.3 13.5 ± 3.4 5.5 ± 2.6
Depression 31.8 ± 10.4 28.5 ± 10.5 19.9 ± 9.1
Anxiety 26.7 ± 4.4 25.2 ± 12.2 15.5 ± 8.3
Table 4
Multivariate regression model of impact of Variation in depression and anxiety on the Variation in sleep quality of participants of the study.
Timing of evaluation Major variable Intervening variable B β 95% Confidence Interval for B R Adjusted R2 P
Lower bound Upper bound
Third evaluation compared to the second
evaluation
Variation of sleep
quality
Variation of depression 0.11 0.23 0.02 0.24 0.57 0.31 0.00
Variation of anxiety 0.17 0.44 0.10 0.21
Third evaluation compared to the ﬁrst
evaluation
Variation of sleep
quality
Variation of depression 0.07 0.22 0.00 0.13 0.41 0.15 0.00
Variation of anxiety 0.07 0.27 0.02 0.13
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because of a maladaptive reaction to a strange and not familiar
environment which staying at, because of the natural course of
abstinence of any drugs which aﬀect the reward pathway and stress
axis of the human brain or because of stopping any beloved and
habitual behavior. Within ﬁve weeks of this study, not only the quality
of sleep was improved, but also the severity of depression and anxiety
reported by patients was reduced. The results demonstrated that only
15% of the recovery occurred in patients' sleep quality can be attributed
to their reduced depression and anxiety symptoms within the ﬁrst four
weeks of quitting methamphetamine (Table 4). Regarding this fact that
the current data are not suﬃcient to understand how amphetamine
users’ sleep pattern changes, the above ﬁnding seems to be the most
important ﬁnding of the present study. The independent recovery of
sleep quality in methamphetamine users not only highlights the
independent neurobiological damages caused across the brain circuits
linked to sleeping process, but also revives hopes to treat the sleep
disorders in patients with amphetamine dependency. Although more
than half of the participants still suﬀered from sleep disorders within
the ﬁfth week after quitting amphetamines, it must be considered that
their sleep quality was improved signiﬁcantly (P=0.00). Since we used
the cut-oﬀ score of 5 for PSQI, the eight-score reduction in the average
score of patients' sleep quality (according to Tables 2, 13.6 ± 3.3change
into 5.5 ± 2.6, which is close to the cut point of 5), can support a good
prognosis for amphetamine-induced sleep disorder. However, the
amphetamine addicts need to be warned about the long period of time
needed to reach full recovery.
This study is important as it tried to measure the sleep quality
(through consecutive measurements) by simultaneously controlling the
intervening variables (suﬀering from medical disorders, psychological
disorders, abusing other substances, using psychotherapeutic medica-
tions, lapse and relapse) during study. In fact, most patients with
amphetamine dependence disorders suﬀer from poly substance depen-
dence disorder as well. Hence, separating the eﬀects of each substance
on sleep-wake cycle which was done in the present study is very
diﬃcult. Also, the high prevalence of comorbidity of amphetamine
dependency with aggression, paranoia, and psychosis [14] often
necessitates prescription of tranquilizers for patients, which aﬀect the
sleep-wake cycle [50]. So studying a pure group of methamphetamine
dependents with no psychiatric comorbidity, which was done in the
present study, may provide promising and valuable data for the
researchers. Moreover, ﬁnding patients who can resist against the
craving for stimulants for four weeks and also agree to cooperate with
psychological assessments is another obstacle which was overcome in
our research.
5. Limitations
This study has its limitations. Lots of patients participated in this
study were male. They were severely aﬀected by methamphetamine
which they prefer to be institutionalized to reach abstinence. Moreover,
the characteristics of the drug used by patients such as dose and
duration of abuse were not addressed. It was due to the unreliable
reports of participants with methamphetamine dependency in terms of
the precise dose and duration, unreliable purity of the illegal drugs they
use, irregular pattern of weekly use (for example times of use could
changes from week to week for an individual) and gradual tolerance to
amphetamines which could attenuate the physiological eﬀects of the
speciﬁc amount of the drug in consumers [10] and reduce correlation
between the characteristic of methamphetamine induced sleep dis-
orders and the amount of methamphetamine which is used.
Given the signiﬁcant improvement in patients' sleep quality within
four weeks of abstaining from using methamphetamines, it would be
better to conduct longer follow-up periods. Therefore, considering
longer follow-up courses alongside applying more objective analysis
tools for sleep disorders (e.g. polysomnographic studies) in designing
future surveys, are suggested.
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